[1] 陈明泉, 李谦, 张琼华, 等. 舒肝宁注射液治疗急慢性病毒性肝炎的临床疗效观察[J]. 肝脏, 2007, 12(3):194-196. doi:  10.3969/j.issn.1008-1704.2007.03.014
[2] 张瑾. 舒肝宁注射液对顺铂中毒小鼠肝脏损伤的保护作用[J]. 中国药房, 2016, 27(7):920-922. doi:  10.6039/j.issn.1001-0408.2016.07.17
[3] 汝锦龙. 中药系统药理学数据库和分析平台的构建和应用[D]. 咸阳: 西北农林科技大学, 2015.
[4] 王艳春, 王建强. 舒肝宁注射液临床应用研究进展[J]. 中国药物警戒, 2020, 17(8):543-548. doi:  10.19803/j.1672-8629.2020.08.20
[5] 刘媛媛, 刘陶, 吴玉梅, 等. 基于雌激素受体调节Nrf2-ARE通路的黄芩中抗氧化成分的筛选[J]. 中国药理学通报, 2019, 35(6):822-827. doi:  10.3969/j.issn.1001-1978.2019.06.017
[6] 朱悦. 异欧前胡素激活LXRα/β介导HMGB1-NLRP3炎症信号通路改善肝纤维化进程的研究[D]. 延吉: 延边大学, 2021.
[7] 陈丹. 山奈酚的抗炎镇痛作用及其机制研究[D]. 南京: 南京中医药大学, 2021.
[8] 郭媛媛, 任锋, 张向颖, 等. 山奈酚对内质网应激诱导的肝细胞损伤的保护及机制[J]. 世界华人消化杂志, 2014, 22(35):5400-5407.
[9] 刘鸣昊, 张丽慧, 马庆亮, 等. 槲皮素对非酒精性脂肪性肝炎大鼠的影响[J]. 中成药, 2019, 41(8):1820-1825. doi:  10.3969/j.issn.1001-1528.2019.08.014
[10]

PANDITH H, ZHANG X B, THONGPRADITCHOTE S, et al. Effect of Siam weed extract and its bioactive component scutellarein tetramethyl ether on anti-inflammatory activity through NF-κB pathway[J]. J Ethnopharmacol,2013,147(2):434-441. doi:  10.1016/j.jep.2013.03.033
[11] 樊江波, 黄琳红. 益母草活性成分芫花素对小鼠凝血及抗炎作用的研究[J]. 西安交通大学学报(医学版), 2019, 40(1):158-161.
[12]

GAO Q, ZHU H W, DONG L Q, et al. Integrated proteogenomic characterization of HBV-related hepatocellular carcinoma[J]. Cell,2019,179(5):1240. doi:  10.1016/j.cell.2019.10.038
[13]

LONG J Y, WANG A Q, BAI Y, et al. Development and validation of a TP53-associated immune prognostic model for hepatocellular carcinoma[J]. EBioMedicine,2019,42:363-374. doi:  10.1016/j.ebiom.2019.03.022
[14]

TOK Y T, ŞENER A G, GÖKMEN A A, et al. Investigation of regulatory T cells and secreted immunomodulatory cytokine IL-10 levels in patients with hepatitis B[J]. Mikrobiyol Bul,2020,54(2):266-278. doi:  10.5578/mb.69340
[15]

HE G B, KARIN M. NF-κB and STAT3 - key players in liver inflammation and cancer[J]. Cell Res,2011,21(1):159-168. doi:  10.1038/cr.2010.183
[16]

MIZUTANI T, SHINODA M, TANAKA Y, et al. Autoantibodies against CYP2D6 and other drug-metabolizing enzymes in autoimmune hepatitis type 2[J]. Drug Metab Rev,2005,37(1):235-252. doi:  10.1081/DMR-200028798
[17]

CHEN X P, WANG H J, XIE W M, et al. Association of CYP1A2 genetic polymorphisms with hepatocellular carcinoma susceptibility: a case-control study in a high-risk region of China[J]. Pharmacogenet Genomics,2006,16(3):219-227. doi:  10.1097/01.fpc.0000194424.20393.c6
[18]

SALUM G M, BADER EL DIN N G, IBRAHIM M K, et al. Vascular endothelial growth factor expression in hepatitis C virus-induced liver fibrosis: a potential biomarker[J]. J Interferon Cytokine Res,2017,37(7):310-316. doi:  10.1089/jir.2016.0127
[19]

DU T, GUO X H, ZHU X L, et al. Association of TNF-alpha promoter polymorphisms with the outcomes of hepatitis B virus infection in Chinese Han population[J]. J Viral Hepat,2006,13(9):618-624. doi:  10.1111/j.1365-2893.2006.00731.x
[20]

EL-KASHEF D H, ABDELRAHMAN R S. Montelukast ameliorates Concanavalin A-induced autoimmune hepatitis in mice via inhibiting TNF-α/JNK signaling pathway[J]. Toxicol Appl Pharmacol,2020,393:114931. doi:  10.1016/j.taap.2020.114931
[21]

ZHANG H Y, BERNUZZI F, LLEO A, et al. Therapeutic potential of IL-17-mediated signaling pathway in autoimmune liver diseases[J]. Mediators Inflamm,2015,2015:436450.
[22]

CHANG M L, YEH C T, CHIEN R N, et al. Overt acute hepatitis B deteriorates in females: destructive immunity with an exaggerated interleukin-17 pathway[J]. Front Immunol,2021,12:631976. doi:  10.3389/fimmu.2021.631976
[23]

HENNIG B J, FIELDING K, BROXHOLME J, et al. Host genetic factors and vaccine-induced immunity to hepatitis B virus infection[J]. PLoS One,2008,3(3):e1898. doi:  10.1371/journal.pone.0001898
[24]

OFFICE F E. Retraction: microRNA-155 modulates hepatic stellate cell proliferation, apoptosis, and cell cycle progression in rats with alcoholic hepatitis via the MAPK signaling pathway through targeting SOCS1[J]. Front Pharmacol,2022,12:840009. doi:  10.3389/fphar.2021.840009